Elicio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Elicio Therapeutics, Inc. (Nasdaq: ELTX), an innovative clinical-stage biotechnology company, is gearing up to deliver a significant presentation at the eagerly awaited H.C. Wainwright 26th Annual Global Investment Conference. Robert Connelly, the Chief Executive Officer of Elicio, will present insights into the company’s cutting-edge approach to immunotherapy for cancer treatment.
Event Details
Taking place on September 11, 2024, at 2:30 p.m. ET, this conference offers a valuable opportunity for investors and stakeholders to gain a deeper understanding of Elicio’s progress in cancer treatment. The presentation will be available via Webcast for registered attendees, allowing them to witness the latest developments in Elicio’s promising pipeline. Additionally, a replay of the event will be accessible on-demand for 90 days after the conference.
About Elicio Therapeutics
Elicio Therapeutics is leading the way in the development of groundbreaking lymph node-targeted immunotherapies. Their innovative strategy harnesses the body’s immune system to more effectively combat cancer. The company’s pipeline includes several promising therapeutic cancer vaccines aimed at targeting specific mutations linked to aggressive cancer types.
Innovative Immunotherapy Solutions
The foundation of Elicio’s advancements lies in their proprietary AMP technology. This technology allows for the precise delivery of therapeutic agents directly to lymph nodes, optimizing the immune response against tumor cells. By enhancing the natural pathways within these crucial immune system sites, Elicio seeks to generate a more vigorous and sustained immune attack on cancer.
Research and Development Pipeline
Elicio's research pipeline showcases several promising candidates in the field of immunotherapy. Notably, ELI-002 targets mKRAS-driven cancers, while ELI-007 and ELI-008 focus on BRAF-driven cancers and p53 hotspot mutations, respectively. Each of these therapies holds the potential to significantly improve outcomes for patients facing some of the most challenging cancer types.
Future Prospects
As a leader in clinical biopharmaceutical advancements, Elicio Therapeutics is committed to driving innovations that align with the ever-evolving landscape of cancer treatment. With ongoing research and development initiatives, the company aims to deliver its pioneering therapies to those who need them most. Investors and the medical community are closely watching their upcoming presentations on the effectiveness of these therapies.
Investor Relations and Contact Information
For any inquiries regarding investor relations, Brian Piekos can be reached directly at Elicio Therapeutics. Interested individuals may contact him via email at IR@elicio.com or by phone at 857-209-0153.
Frequently Asked Questions
What is the significance of Elicio's upcoming presentation?
The presentation will shed light on Elicio's immunotherapy research and its potential implications for cancer treatment.
When and where will the presentation take place?
The presentation is scheduled for September 11, 2024, at the H.C. Wainwright 26th Annual Global Investment Conference.
What technologies does Elicio utilize in its therapies?
Elicio employs AMP technology to deliver therapeutic agents directly to lymph nodes, thereby enhancing the immune response to cancer.
What cancers do Elicio's therapeutic vaccines target?
Elicio's vaccines are designed to target aggressive cancers, specifically mKRAS-driven and BRAF-driven cancers, along with p53 hotspot mutations.
How can investors learn more about Elicio's developments?
Investors can obtain further information through the company's investor relations contact, Brian Piekos, at IR@elicio.com.
